Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | FABP2 | P12104 | 1/20 | 0.68 |
| ▸ | PPARG | P37231 | 1/20 | 0.68 |
| ▸ | PPARD | Q03181 | 1/20 | 0.68 |
| ▸ | PPARA | Q07869 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154123 | 0.97 | DNMT3A (0.66) | DNMT3AALDH1A1FABP2PPARGPPARD | |
| SCHEMBL1153879 | 0.92 | ALDH1A1 (0.58) | DNMT3AALDH1A1FABP2PPARGPPARD | |
| SCHEMBL1153988 | 0.91 | DNMT3A (0.60) | DNMT3AALDH1A1FABP2PPARGPPARD | |
| SCHEMBL1154718 | 0.90 | DNMT3A (0.59) | DNMT3AALDH1A1FABP2PPARGPPARD | |
| SCHEMBL1154562 | 0.90 | ALDH1A1 (0.56) | DNMT3AALDH1A1FABP2PPARGPPARD | |
| SCHEMBL5323204 | 0.89 | PPARA (0.58) | DNMT3AALDH1A1FABP2PPARGPPARD | |
| SCHEMBL1154442 | 0.89 | DNMT3A (0.58) | DNMT3AALDH1A1FABP2PPARGPPARD | |
| SCHEMBL11711852 | 0.89 | DNMT3A (0.66) | DNMT3AALDH1A1HDAC1HDAC6NLRP3 | |
| SCHEMBL1154171 | 0.89 | DNMT3A (0.66) | DNMT3AALDH1A1HDAC1HDAC6NLRP3 | |
| SCHEMBL1154002 | 0.89 | DNMT3A (0.60) | DNMT3AALDH1A1FABP2PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795310-B2 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2010-09-14 | — | — | US | claimed |
| US-7795310-B2 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1781303-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX INC (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1781303-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | CombinatoRx, Incorporated (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| WO-2006004803-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | LIPC, PNLIP, GOT2 | DNMT3A 615/4885ALDH1A1 626/4885FABP2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.